Clinical Trial Update: A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy [Phase 2]

View source ↗

Summary

This document reports the termination of a Phase II trial of single-agent dovitinib in advanced malignant pleural mesothelioma that progressed after prior plati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Dovitinib (dovitinib)

Snippet

Sponsor: Ontario Clinical Oncology Group (OCOG) | Conditions: Advanced Malignant Pleural Mesothelioma, MPM | Phase 2 | Status: TERMINATED